Personal profile
Research Strategic Pillar
The Chief Research Officer, has determined that UTMB research should be prioritized into six health communities. This researcher has received the following badge(s):
Education/Academic qualification
MD, Tulane University School of Medicine - New Orleans, LA
… → 1988
Research Strategic Pillar Keywords
- Infectious/ Immunological Health
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
A Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of CAL02 Administered Intravenously in Addition to Standard of Care in Subjects with Severe Community-Acquired Bacterial Pneumonia (SCABP)
McLellan, S. (PI)
Eagle Pharmaceuticals, Inc ( Award # )
3/8/24 → 3/7/28
Project: Research project
-
Regional Emerging Special Pathogen Treatment Center Cooperative Agreement
McLellan, S. (PI)
Administration for Strategic Preparedness Response ( Award #5U3REP2206790400)
9/30/22 → 9/29/27
Project: Research project
-
National Ebola Training and Education
McLellan, S. (PI)
Emory University ( Award #6U3REP1505490524)
6/30/23 → 6/29/24
Project: Research project
-
National Ebola Training and Education Center
McLellan, S. (PI)
Emory University ( Award #U3REP1505490516)
6/30/22 → 6/29/23
Project: Research project
-
Hospital Preparedness Program (HPP) Ebola Preparedness and Response Activities
McLellan, S. (PI)
Texas Department of State Health Services ( Award #U3REP150543)
6/15/22 → 6/14/23
Project: Research project
-
Nipah virus: a summary for clinicians
On behalf of the State of the Science Working Group of the National Ebola Training and Education Center’s (NETEC’s) Special Pathogens Research Network (SPRN), Dec 2025, In: International Journal of Emergency Medicine. 18, 1, 126.Research output: Contribution to journal › Review article › peer-review
Open Access3 Link opens in a new tab Scopus citations -
Immunomodulators for immunocompromised patients hospitalized for COVID-19: a meta-analysis of randomized controlled trials
CORIMUNO-19 Collaborative Group, DisCoVeRy Study Group, ACTT-2 Study Group & ACTT-3 Study Group, Mar 2024, In: EClinicalMedicine. 69, p. 102472 102472.Research output: Contribution to journal › Article › peer-review
Open Access9 Link opens in a new tab Scopus citations -
Safety and immunogenicity of a delayed booster dose of the rVSVΔG-ZEBOV-GP vaccine for prevention of Ebola virus disease: a multicentre, open-label, phase 2 randomised controlled trial
Davey, R. T., Collins, G. L., Rouphael, N., Poliquin, G., McConnell, R., Grubbs, G., Moir, S. L., Langley, J. M., Teitelbaum, M., Hewlett, A. L., McLellan, S. L. F., Bhadelia, N., Raabe, V. N., Mulligan, M. J., Maljkovic Berry, I., Dighero-Kemp, B., Kurtz, J. R., Hensley, L. E., Dozier, N. C. E. & Marron, L. C. B. & 6 others, , Nov 2024, In: The Lancet Microbe. 5, 11, 100923.Research output: Contribution to journal › Article › peer-review
Open Access6 Link opens in a new tab Scopus citations -
Select Agent Regulatory Challenges in a Patient Care Setting: Review and Recommendations
Mears, M. C., Ntiforo, C. A., Sauer, L. M., Mehta, A. K., Levine, C. B., Broadhurst, J., Davey, R., Evans, J., Herrera, V., Iwen, P., Kortepeter, M., Piccolo, A. L., McLellan, S. & Uyeki, T., Feb 1 2024, In: Health Security. 22, 1, p. 58-64 7 p.Research output: Contribution to journal › Article › peer-review
-
The alarmin IL-33 exacerbates pulmonary inflammation and immune dysfunction in SARS-CoV-2 infection
Wang, H., Hosakote, Y. M., Boor, P. J., Yang, J., Zhang, Y., Yu, X., Gonzales, C., Levine, C. B., McLellan, S., Cloutier, N., Xie, X., Shi, P. Y., Ren, P., Hu, H., Sun, K., Soong, L., Sun, J. & Liang, Y., Jun 21 2024, In: iScience. 27, 6, p. 110117 110117.Research output: Contribution to journal › Article › peer-review
Open Access9 Link opens in a new tab Scopus citations